News | January 06, 2009

Medrad Sponsors PET Study at University of Zurich

January 6, 2009 - MEDRAD has agreed to collaborate with the University of Zurich in a study on dynamic PET imaging with the MEDRAD Intego PET Infusion System, in which researchers will utilize MEDRAD’s system for controlling the radioactive dose delivered during PET imaging procedures.

The study will examine patients with tumors in the chest or abdomen and compare standard quantitative techniques, such as standard uptake value (SUV), with more advanced kinetic and compartmental models. One of the primary goals of the research is to explore how controlled delivery technology can enable dynamic imaging by providing additional clinical utility and making these advanced techniques more practical. By enabling the benefit of repeatable infusion of the prescribed FDG dose to all subjects in the study, the Intego System is a key element in the research.

“The research will explore the clinical viability of dynamic imaging with PET,” said Alfred Buck, M.D., University of Zurich (Switzerland). The University of Zurich is a leading institution in dynamic PET research, and has licensed its proprietary FDG delivery technology to MEDRAD for use in the Intego PET Infusion System.

The Intego System is designed to automatically extract a patient dose from a multi-dose vial and delivers it directly to the patient, virtually eliminating manual dose preparation and handling, and the corresponding radiation exposure to the technologist inherent in manual preparation. With the Intego System’s dose-on-demand capability, the prescribed dose can be delivered when the patient and clinician are ready. This should enable the clinician to respond to schedule changes, patient delays and add-on patients.

The system’s features include real-time dose availability information, an integrated ionization chamber and an optional weight-based dose calculation, that allow the healthcare provider to more precisely customize each patient’s dose. Safety features include a tungsten multi-dose vial shield, a fully lead-lined mobile cart, and an automated saline flush to remove residual FDG from the line after each infusion.

For more information: www.medrad.com

Related Content

the Contrast Media Injectors Market is estimated to be USD 1.3 billion in 2020 and  projected to reach $1.9B by 2025, at a CAGR of 7.4% between 2020 and 2025

Getty Images

News | Contrast Media Injectors | September 02, 2020
September 2, 2020 — According to the new market research report "...
The Global Contrast Injectors Market will grow by $613.47M during 2020-2024, according to Technavio
News | Contrast Media Injectors | June 17, 2020
June 17, 2020 — Technavio has been monitoring the ...
The FDA has approved Lilly’s TAUVID (flortaucipir F 18 injection), a radioactive diagnostic agent, for PET imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease

Getty Images

News | Contrast Media | June 01, 2020
June 1, 2020 — TAUVID, a radioactive diagnostic agent, has been approved by the FDA for...
This image is of an 80 kg woman with a newly diagnosed IDH-wildtype glioblastoma

This image is of an 80 kg woman with a newly diagnosed IDH-wildtype glioblastoma. The quarter dose image on the left was obtained after the administration of 4 ml of MultiHance. Subsequently, an additional 12 ml of MultiHance was administered and the cumulative full dose image in the center was obtained. The image on the right was rendered following artificial intelligence processing of the 4 ml image using eGad genetic algorithms. This image has the quality of triple dose gadolinium even though only one quarter dose gadolinium was given.

Feature | Contrast Media Injectors | January 30, 2020 | By Matthew Kuhn, M.D., FACR
Gadolinium-based contrast agents (...

Image courtesy of Guerbet

Feature | Contrast Media Injectors | January 30, 2020 | By Melinda Taschetta-Millane
Contrast media injector technology has seen several recent advances, such as cutting costs by reducing contrast waste

Guerbet presented its Contrast&Care injection management solution at ECR 2018

News | Contrast Media | November 13, 2019
November 13, 2019 – Guerbet, a global specialist in...
Windsong Radiology Group

Windsong Radiology Group

Sponsored Content | Case Study | Contrast Media Injectors | October 30, 2019
Windsong Radiology Group is a New York-based radiolo